Fly News Breaks for December 6, 2019
Dec 6, 2019 | 10:04 EDT
H.C. Wainwright analyst Vernon Bernardino raised his price target on Cassava Sciences to $6 from $3 and reiterated his Buy rating on the stock following the company's presentation of data at the Clinical Trials on Alzheimer's Disease, or CTAD, conference. He believes the additional Phase 2a clinical data for PTI-125, the company's investigational drug candidate for AD, presented at the meeting were positive and thinks results from the ongoing Phase 2b study in patients with mild-to-moderate AD can be a catalyst for the stock in mid-2020.
News For SAVA From the Last 2 Days
There are no results for your query SAVA